Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 6/20 | 0.62 |
| ▸ | CACNA1B | Q00975 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
| ▸ | CCR9 | P51686 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3486170 | 0.92 | NR1I2 (0.62) | NR1I2CACNA1BALDH1A1KDM4EPOLB | |
| SCHEMBL3485639 | 0.87 | NR1I2 (0.70) | NR1I2CACNA1BALDH1A1KDM4EGAA | |
| SCHEMBL8152681 | 0.77 | NR1I2 (1.00) | NR1I2CACNA1BALDH1A1KDM4EPOLB | |
| SCHEMBL13401206 | 0.72 | NR1I2 (0.53) | NR1I2CACNA1BALDH1A1KDM4EPOLB | |
| SCHEMBL8157437 | 0.72 | CACNA1B (0.84) | NR1I2CACNA1BALDH1A1KDM4EGAA | |
| SCHEMBL8157762 | 0.70 | NR1I2 (1.00) | NR1I2CACNA1BALDH1A1KDM4EGAA | |
| SCHEMBL8156552 | 0.69 | CACNA1B (1.00) | NR1I2CACNA1BALDH1A1KDM4EGAA | |
| SCHEMBL8143702 | 0.69 | CACNA1B (0.83) | NR1I2CACNA1BALDH1A1KDM4EGAA | |
| SCHEMBL18733287 | 0.68 | ABCB11 (0.51) | ALDH1A1KDM4EGAAMEN1KMT2A | |
| SCHEMBL8689468 | 0.67 | ALDH1A1 (0.55) | ALDH1A1KDM4EPOLBGAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087446-A1 | 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK SHARP & DOHME CORP. | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087446-A1 | 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | TRPV1, CACNA1S, TRPV2 | NR1I2 1761/4885CACNA1B 13/4885ALDH1A1 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.